Published in Med Sci Monit on November 28, 2016
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
NeuN, a neuronal specific nuclear protein in vertebrates. Development (1992) 10.82
The role of CXC chemokines and their receptors in cancer. Cancer Lett (2008) 3.84
Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol (2012) 3.26
CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity (2002) 2.67
Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther (2010) 2.27
The chemokine system and cancer. J Pathol (2011) 2.05
Chemokine CXCL13 is essential for lymph node initiation and is induced by retinoic acid and neuronal stimulation. Nat Immunol (2009) 1.71
Chemokines: integrators of pain and inflammation. Nat Rev Drug Discov (2005) 1.68
Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc Natl Acad Sci U S A (2002) 1.55
Chemokines and pain mechanisms. Brain Res Rev (2008) 1.43
Chemokines and cytokines in neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol (2011) 1.36
Morphine peripheral analgesia depends on activation of the PI3Kgamma/AKT/nNOS/NO/KATP signaling pathway. Proc Natl Acad Sci U S A (2010) 1.34
Bone cancer pain. Ann N Y Acad Sci (2010) 1.28
Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis Rheum (2008) 1.26
CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis. Arthritis Rheum (2007) 1.23
The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis. J Neuroinflammation (2009) 1.22
Pain and the immune system. Br J Anaesth (2008) 1.18
Cancer Pain: A Critical Review of Mechanism-based Classification and Physical Therapy Management in Palliative Care. Indian J Palliat Care (2011) 1.14
Opioid receptor-triggered spinal mTORC1 activation contributes to morphine tolerance and hyperalgesia. J Clin Invest (2014) 1.11
Mechanisms underlying morphine analgesic tolerance and dependence. Front Biosci (Landmark Ed) (2009) 1.10
Mechanisms of cancer-induced bone pain. Clin Oncol (R Coll Radiol) (2011) 1.09
CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford) (2010) 1.08
Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett (2009) 1.07
Challenges in cancer pain management--bone pain. Eur J Cancer (2008) 1.07
Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. J Rheumatol (2009) 1.07
Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers. J Pain (2011) 1.06
B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE). Nephrol Dial Transplant (2009) 1.06
A distinct human CD4+ T cell subset that secretes CXCL13 in rheumatoid synovium. Arthritis Rheum (2013) 1.03
Blocking EphB1 receptor forward signaling in spinal cord relieves bone cancer pain and rescues analgesic effect of morphine treatment in rodents. Cancer Res (2011) 1.02
Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci U S A (2014) 1.01
CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5. J Clin Invest (2016) 0.92
Spinal IFN-γ-induced protein-10 (CXCL10) mediates metastatic breast cancer-induced bone pain by activation of microglia in rat models. Breast Cancer Res Treat (2013) 0.90
Activation of c-jun N-terminal kinase in spinal cord contributes to breast cancer induced bone pain in rats. Mol Brain (2012) 0.88
NFκB-mediated CXCL1 production in spinal cord astrocytes contributes to the maintenance of bone cancer pain in mice. J Neuroinflammation (2014) 0.87
Differential activation of the μ-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model. Br J Pharmacol (2013) 0.87
Opioid and chemokine receptor crosstalk: a promising target for pain therapy? Nat Rev Neurosci (2015) 0.87
Interactions between chemokine and mu-opioid receptors: anatomical findings and electrophysiological studies in the rat periaqueductal grey. Brain Behav Immun (2010) 0.86
Involvement of CX3CR1 in bone cancer pain through the activation of microglia p38 MAPK pathway in the spinal cord. Brain Res (2012) 0.86
Use of Animal Models in Understanding Cancer-induced Bone Pain. Cancer Growth Metastasis (2015) 0.83
Involvement of spinal monocyte chemoattractant protein-1 (MCP-1) in cancer-induced bone pain in rats. Neurosci Lett (2012) 0.83
CXCR3: latest evidence for the involvement of chemokine signaling in bone cancer pain. Exp Neurol (2015) 0.81
Cancer induced bone pain. BMJ (2015) 0.81
Chemokines and Their Receptors: Potential Therapeutic Targets for Bone Cancer Pain. Curr Pharm Des (2015) 0.80
Inhibition of morphine tolerance is mediated by painful stimuli via central mechanisms. Drug Discov Ther (2012) 0.80